Fidelity Investments
INKT icon

Fidelity Investments’s MiNK Therapeutics INKT Stock Holding History

Fidelity Investments’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Hold
0
– -$1 – 5513
2024
Q4 		– Hold
0
– – – 5513
2024
Q1 		– Sell
-9
Closed -$100 – 5544
2023
Q4 		$100 Buy
9
+3
+50% +$31 ﹤0.01% 4944
2023
Q3 		$70 Sell
6
-943
-99% -$15.4K ﹤0.01% 4895
2023
Q2 		$19.9K Buy
+949
New +$19K ﹤0.01% 3859
2022
Q3 		– Sell
-37
Closed -$1K – 5157
2022
Q2 		$1K Buy
37
+21
+131% +$396 ﹤0.01% 4734
2022
Q1 		$0 Buy
+16
New +$481 ﹤0.01% 5227

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
C
Covestor London, United Kingdom $144M AUM 37.32% 1-Year Est. Return

Fidelity Investments's INKT Position: Q1 2025 in Review

Fidelity Investments held its MiNK Therapeutics (INKT) position steady in Q1 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5513.

Fidelity Investments first reported a position in INKT in Q1 2022 and has held it in 5 quarters since. The position peaked at $19.9K in Q2 2023. 17 funds tracked by Wall St. Rank hold INKT as of Q1 2025.

  • Fidelity Investments held 0 shares of MiNK Therapeutics worth $0 as of Q1 2025.
  • Fidelity Investments left its MiNK Therapeutics share count unchanged in Q1 2025.
  • MiNK Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2025, its #5513 holding.
  • Fidelity Investments first reported a position in MiNK Therapeutics in Q1 2022 and has held it in 5 quarters since.
  • Fidelity Investments's MiNK Therapeutics position peaked at $19.9K in Q2 2023.
  • 17 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2025.

Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.